WEDNESDAY, Sept. 18, 2024 -- Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b...
Vous n'êtes pas connecté
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant modified 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan...
WEDNESDAY, Sept. 18, 2024 -- Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly type of pancreatic cancer. It’s aggressive, meaning it grows fast and spreads quickly....
THURSDAY, Sept. 19, 2024 -- For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by...
THURSDAY, Sept. 19, 2024 -- For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer...
FRIDAY, Sept. 20, 2024 -- Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk...
23 September 2024 -- High-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd) compared to...
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated...
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia, a common condition related to...
In a recent study published in the scientific journal "Blood", researchers from MedUni Vienna show that hemorrhages are more common in cancer patients...